Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $80.91 USD
Change Today 0.00 / 0.00%
Volume 0.0
SHPGF On Other Exchanges
Symbol
Exchange
SHPGF is not on other exchanges.
As of 8:10 PM 03/25/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHPGF) Snapshot

Open
$82.81
Previous Close
$80.91
Day High
$82.81
Day Low
$80.69
52 Week High
09/29/14 - $87.45
52 Week Low
04/15/14 - $47.17
Market Cap
47.8B
Average Volume 10 Days
921.2
EPS TTM
--
Shares Outstanding
590.2M
EX-Date
03/12/15
P/E TM
--
Dividend
$15.05
Dividend Yield
0.28%
Current Stock Chart for SHIRE PLC (SHPGF)

shire plc (SHPGF) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc (SHPGF) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc (SHPGF) Key Developments

Shire plc Announces Availability of New Titration Strength of ADHD Drug

Shire plc has announced the availability of Vyvanse 10mg capsules indicated for the treatment of attention-deficit/hyperactivity disorder, or ADHD. This new titration dose, which was approved by the FDA on October 30, 2014, is the seventh Vyvanse dosage strength available in addition to the 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsule strengths. In July 2014, Shire received approval for two additional administration options for Vyvanse capsules. In addition to swallowing whole or mixing the capsule contents with water, the contents can be mixed with yogurt or orange juice for patients who have trouble swallowing capsules.

Shire Reportedly Mulls Acquisition Of Ironwood Pharmaceuticals

Shire plc (LSE:SHP) is reportedly seeking acquisition of Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD). Market sources reported that Ironwood Pharmaceuticals has been approached by European suitors, including Shire, 35p better at 5635p, and rejected cash offers in the region of $30 a share. Ironwood Pharma jumped 5% to $16.47.

Genfit Reportedly Mulls Sale

Genfit SA (ENXTPA:GNFT) is reportedly exploring the option of selling itself. According to people familiar with the matter, Genfit SA has also held preliminary discussions with potential strategic buyers. According to the sources, Genfit has yet not made a any decision and there is a possibility that it may not sell at all. The potential buyers include Sanofi (ENXTPA:SAN), Shire plc (LSE:SHP) and Novartis AG (SWX:NOVN).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPGF:US $80.91 USD 0.00

SHPGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$91.85 AUD +0.15
Eisai Co Ltd ¥8,803 JPY -115.00
Hospira Inc $87.85 USD +0.10
Mylan NV $61.88 USD +0.65
UCB SA €67.62 EUR -0.63
View Industry Companies
 

Industry Analysis

SHPGF

Industry Average

Valuation SHPGF Industry Range
Price/Earnings 14.5x
Price/Sales 7.8x
Price/Book 5.4x
Price/Cash Flow 13.9x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.